624 related articles for article (PubMed ID: 23543481)
1. Phosphate binders in moderate chronic kidney disease: where do we stand?
Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D
J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481
[TBL] [Abstract][Full Text] [Related]
2. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
3. Use of phosphate binders in chronic kidney disease.
Ketteler M; Biggar PH
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
[TBL] [Abstract][Full Text] [Related]
4. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
5. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
6. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
7. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
[TBL] [Abstract][Full Text] [Related]
8. [Phosphate binders in chronic kidney disease: the positions of sevelamer].
Fomin VV; Shilov EM; Svistunov AA; Milovanov IuS
Ter Arkh; 2013; 85(6):96-9. PubMed ID: 23875200
[TBL] [Abstract][Full Text] [Related]
9. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
Spatz C; Roe K; Lehman E; Verma N
Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
[TBL] [Abstract][Full Text] [Related]
10. Use of Phosphorus Binders among Non-Dialysis Chronic Kidney Disease Patients and Mortality Outcomes.
Bhandari SK; Liu IA; Kujubu DA; Huynh T; Behayaa H; Kovesdy CP; Kalantar-Zadeh K; Jacobsen SJ; Sim JJ
Am J Nephrol; 2017; 45(5):431-441. PubMed ID: 28445887
[TBL] [Abstract][Full Text] [Related]
11. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
Moe SM; Radcliffe JS; White KE; Gattone VH; Seifert MF; Chen X; Aldridge B; Chen NX
J Bone Miner Res; 2011 Nov; 26(11):2672-81. PubMed ID: 21826734
[TBL] [Abstract][Full Text] [Related]
12. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
13. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
14. The challenge of controlling phosphorus in chronic kidney disease.
Cannata-Andía JB; Martin KJ
Nephrol Dial Transplant; 2016 Apr; 31(4):541-7. PubMed ID: 25770169
[TBL] [Abstract][Full Text] [Related]
15. [Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].
Malberti F
G Ital Nefrol; 2010; 27 Suppl 52():S47-54. PubMed ID: 21132662
[TBL] [Abstract][Full Text] [Related]
16. Hyperphosphatemia and phosphate binders: effectiveness and safety.
Kalaitzidis RG; Elisaf MS
Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
[TBL] [Abstract][Full Text] [Related]
17. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.
Scialla JJ; Kendrick J; Uribarri J; Kovesdy CP; Gutiérrez OM; Jimenez EY; Kramer HJ
Am J Kidney Dis; 2021 Jan; 77(1):132-141. PubMed ID: 32771650
[TBL] [Abstract][Full Text] [Related]
18. Phosphate management in chronic kidney disease.
Bhan I
Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):174-9. PubMed ID: 24445424
[TBL] [Abstract][Full Text] [Related]
19. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
Martin KJ; González EA
Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
[TBL] [Abstract][Full Text] [Related]
20. Practice patterns of phosphate binder use and their associations with mortality in chronic kidney disease.
Navaneethan SD; Sakhuja A; Arrigain S; Sharp J; Schold JD; Nally JV
Clin Nephrol; 2014 Jul; 82(1):16-25. PubMed ID: 24887302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]